Remarkable advances in technologies for assaying gene expression and the availability of high-throughput data have opened up new avenues of cancer research that may allow researchers to generate hypotheses regarding improved disease classification.
It may also allow research studies to more clearly separate the intervention and evaluation arms of their research.
The authors suggested various measures that may allow future research to isolate more clearly the effects of intervention itself: enhancing diversity, blinding participants, simplifying assessments, and using analytic techniques to limit the impact of outliers and regression to the mean.
There are a paucity of data linking post-treatment AMH to the clinically important variables of reproductive lifespan and fertility but the development of new assays able to detect low levels of AMH may allow further research to explore these relationships.
Here, we discuss CRISPR research on each of the ten hallmarks of cancer, outline potential barriers for its clinical implementation and speculate on the advances it may allow in cancer research in the near future.
The articulation of this theoretically and empirically based framework may allow for posing research questions about program effectiveness, such as what is the relative relationship of the program components to participant outcomes (e.g., research productivity, commitment to research career, actual career entry)?
Highlighting these shared and separate research aims may allow test developers and researchers to focus on potential clinical uses of new genetic tests.
A more organized approach to technology-assisted education research may allow educators across specialties to learn from each other.
On the other hand, the synergies between Nokia and Alcatel-Lucent may allow it to cut research and development costs and deploy new services, including 5G infrastructure, more quickly.
Giving radiology department staff the opportunity to learn the history, regulatory requirements, and outcomes of research may allow them to more fully participate in the collection of data and improve patient care.
